References

• Bang, S., Yu, J., Chung, J. H., Song, W., Kang, M., Sung, H. H., Jeon, H. G., Jeong, B. C., Seo, S. I., Lee, H. M., & Jeon, S. S. (2021). Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels. Scientific Reports, 11(1), 21951.
• Boesen, L., Nørgaard, N., Løgager, V., Balslev, I., Bisbjerg, R., Thestrup, K.-C., Jakobsen, H., & Thomsen, H. S. (2019). Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7–10 Prostate Cancer in Biopsy-naïve Men. European Urology Oncology, 2(3), 311–319.
• Cao, L., Lee, C. H., Ning, J., Handy, B. C., Wagar, E. A., & Meng, Q. H. (2018). Combination of prostate cancer antigen 3 and Prostate- Specific antigen improves diagnostic accuracy in men at risk of prostate cancer. Archives of Pathology & Laboratory Medicine, 142(9), 1106–1112.
• Carlsson, S. V., Arnsrud Godtman, R., Pihl, C.-G., Vickers, A., Lilja, H., Hugosson, J., & MÃ¥nsson, M. (2023). Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow- up of the Göteborg Randomized Population- based Prostate Cancer Screening Trial. European Urology, 83(2), 103–109.
• Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., DeKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T., & Southwick, P. C. (1994). Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. The Journal of Urology, 151(5), 1283–1290.
• Choi, H., Cho, S., Bae, J. H., Lee, S. E., Hong, S. K., Moon, D. G., Cheon, J., Byun, S.-S., & Park, J. Y. (2017). Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter. Urologia Internationalis, 99(2), 143–148.
• De Koning, H. J., Gulati, R., Moss, S., Hugosson, J., Pinsky, P. F., Berg, C. D., Auvinen, A., Andriole, G. L., Roobol, M. J., Crawford, E. D., Nelen, V., Kwiatkowski, M., Zappa, M., Luján, M., Villers, A., De Carvalho, T. M., Feuer, E. J., Tsodikov, A., Mariotto, A. B., . . . Etzioni, R. (2017). The efficacy of prostate- specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer, 124(6), 1197–1206.
• Ikuerowo, S., Ajala, M., Abolarinwa, A., & Omisanjo, O. (2016). Age-specific serum prostate specific antigen ranges among apparently healthy Nigerian men without clinical evidence of prostate cancer. Nigerian Journal of Surgery, 22(1), 5.
• Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ (Clinical Research Ed.), 362, k3519.
• Jiao, B., Gulati, R., Hendrix, N., Gore, J. L., Soroush Rais-Bahrami, Morgan, T. M., & Etzioni, R. (2021). Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. Value in Health, 24(8), 1111–1117.
• Lavallée, L. T., Binette, A., Witiuk, K., Cnossen, S., Mallick, R., Fergusson, D. A., Momoli, F., Morash, C., Cagiannos, I., & Breau, R. H. (2016). Reducing the Harm of Prostate Cancer Screening: Repeated Prostate- Specific Antigen Testing. Mayo Clinic Proceedings, 91(1), 17–22.
• Lee, D. J., Mallin, K., Graves, A. J., Chang, S. S., Penson, D. F., Resnick, M. J., & Barocas, D. A. (2017). Recent Changes in Prostate Cancer Screening Practices and Epidemiology. Journal of Urology, 198(6), 1230–1240.
• Mahal, B. A., Aizer, A. A., Efstathiou, J. A., & Nguyen, P. L. (2015). Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer, 122(1), 78–83.
• Merriel, S. W. D., Pocock, L., Gilbert, E., Creavin, S., Walter, F. M., Spencer, A., & Hamilton, W. (2022). Systematic review and meta- analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Medicine, 20(1).
• Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M., De Santis, M., Fossati, N., Gross, T., Henry, A., Joniau, S., Lam, T., Mason, M. D., Матвеев, Ð’. Б., Moldovan, P. C., Van Den Bergh, R. C., Van Den Broeck, T., Van Der Poel, H. G., Van Der Kwast, T. H., Rouvière, O., . . . Cornford, P. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 71(4),618–629.
• Ola, I. O., Talala, K., Tammela, T. L., Taari, K., Murtola, T. J., Kujala, P., Raitanen, J., & Auvinen, A. (2022). Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/ mL : The Finnish Randomized Study of Screening for Prostate Cancer. International Journal of Cancer, 152(4), 672–678.
• Roth, J. A., Gulati, R., Gore, J. L., Cooperberg, M. R., & Etzioni, R. (2016). Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncology, 2(7), 890.
• Spratt, D. E., Dai, D., Den, R. B., Troncoso, P., Yousefi, K., Ross, A. E., Schaeffer, E. M., Haddad, Z., Elai Davicioni, Mehra, R., Morgan, T. M., Rayford, W., Firas Abdollah, Trabulsi, E. J., Achim, M., Li, E., Guerrero, M., R. Jeffrey Karnes, Dicker, A. P., & Hurwitz, M. A. (2018). Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate- specific Antigen Persistence Postprostatectomy. European Urology, 74(1), 107–114.